[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350474-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350474-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","repurposing-antiretroviral-drugs-for-urological-cancers-differential-effects-of-protease-inhibitors-and-nnrtis","Repurposing Antiretroviral Drugs for Urological Cancers - Differential Effects of Protease Inhibitors and NNRTIs","","Drug repurposing offers a promising oncology strategy for urological prostate and bladder cancers, where resistance to current treatments remains a major obstacle. This study assessed anticancer activity of ritonavir (RIT), saquinavir (SAQ), and rilpivirine (RPV) in PC-3 and UM-UC-5 cells using MTT, clonogenic assays, wound healing, fibroblast toxicity testing, and DCFDA for intracellular ROS, including efavirenz and etravirine. RIT and SAQ showed stronger antiproliferative effects than RPV, while migration effects were limited.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/repurposing-antiretroviral-drugs-for-urological-cancers-differential-effects-of-protease-inhibitors-and-nnrtis/350474/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/repurposing-antiretroviral-drugs-for-urological-cancers-differential-effects-of-protease-inhibitors-and-nnrtis/350474.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which antiretroviral drugs showed the strongest anticancer effects in prostate and bladder cancer cells?","Question",{"text":63,"@type":64},"Protease inhibitors ritonavir and saquinavir produced stronger antiproliferative and anti-clonogenic effects than the NNRTI rilpivirine in PC-3 and UM-UC-5 cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Do these antiretroviral drugs strongly affect cancer cell migration?",{"text":68,"@type":64},"Effects on cell migration were limited across all tested drugs, indicating migration impairment is not a dominant outcome.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the drugs influence intracellular ROS levels, and what was the toxicity profile?",{"text":72,"@type":64},"ROS production depended on the cell line and drug: efavirenz increased ROS in PC-3, while saquinavir and ritonavir increased ROS in UM-UC-5 cells. Overall toxicity was minimal in non-malignant cells, with some toxicity for saquinavir only at concentrations higher than those needed for anticancer activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350474,1790397396,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nRepurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIson Prostate and Bladder Cancer Cells  \nMariana Pereira 1,2,3 and Nuno Vale 1,3,4, *  \nReceived: 25 April 2026  \nRevised: 4 June 2026  \nAccepted: 5 June 2026  \nPublished: 7 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal; [mariana.m.pereira2097@gmail.com](mariana.m.pereira2097@gmail.com)  \n2 ICBAS—School of Medicine and Biomedical Sciences, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal  \n3 RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal  \n4 Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal  \n* [Correspondence: nunovale@med.up.pt](Correspondence: nunovale@med.up.pt); Tel.: +351-220-426-537  \nHighlights  \nWhat are the main findings?  \n• Protease inhibitors (ritonavir and saquinavir) showed stronger antiproliferative and anti-clonogenic effects than the NNRTI rilpivirine in prostate (PC-3) and bladder (UM-UC-5) cancer cells.  \n• Antiretroviral drugs had limited effects on cell migration but modulated intracellular ROS levels in a cell-dependent manner, with low toxicity in healthy cells.  \nWhat are the implications of the main findings?  \n• Antiretroviral drugs may preferentially target cancer cell-related proliferation and long-term survival rather than migration capacity.  \n• Their effects are concentration-and cell-line-dependent.  \nAbstract  \nDrug repurposing presents as a promising strategy in oncology, particularly for urological prostate and bladder cancers, where resistance to current therapy remains a challenge. This study evaluated the anticancer potential of three antiretroviral drugs, namely ritonavir (RIT), saquinavir (SAQ), and rilpivirine (RPV), in PC-3 and UM-UC-5 cancer cell lines, using MTT, clonogenic, wound healing, toxicity assessment with fibroblast cells, and DCFDA assays; this last method included efavirenz (EFV) and etravirine (ETV) for intracellular reactive oxygen species (ROS) production. RIT and SAQ showed stronger antiproliferative effects than RPV, with lower concentration-and cell-line-dependent activity, while clonogenic assays confirmed a reduction in long-term proliferation, particularly for RIT in both cell lines and SAQ for UM-UC-5 . In contrast, effects on cell migration were limited for all drugs. ROS production was cell-dependent, with EFV increasing ROS in PC-3 and SAQ and RIT in UM-UC-5 cells. Generally, all drugs showed minimal toxicity in non-malignant cells, with SAQ exhibiting some toxicity but only for concentrations higher than those required for anticancer activity. Overall, these findings suggest that antiretroviral, especially protease inhibitors, may cause anticancer effects, although these are concentration-and context-dependent, and further investigation is needed to understand the mechanisms involved.  \nKeywords: drug repurposing; urological cancer; antiretrovirals; cancer therapy  \n1. Introduction  \nAlthough considerable progress has been made in cancer diagnosis and treatment, this disease remains a major worldwide health burden, with high incidence and mortality [1] . Among urological malignancies, prostate and bladder cancer still have a high prevalence and mortality rates, particularly due to disease progression to metastasis and development of resistance to therapy [2] . This highlights the need for alternative therapeutic approaches capable of complement","cbCaimCO4ZlUeLXe","https://ap.wps.com/l/cbCaimCO4ZlUeLXe","pdf",3285648,17,"English","# Introduction\n# Materials and Methods\n# Results\n## Antiproliferative and clonogenic effects\n## Cell migration and ROS modulation\n## Toxicity in non-malignant cells\n# Discussion\n# Conclusions","[{\"question\":\"Which antiretroviral drugs showed the strongest anticancer effects in prostate and bladder cancer cells?\",\"answer\":\"Protease inhibitors ritonavir and saquinavir produced stronger antiproliferative and anti-clonogenic effects than the NNRTI rilpivirine in PC-3 and UM-UC-5 cells.\"},{\"question\":\"Do these antiretroviral drugs strongly affect cancer cell migration?\",\"answer\":\"Effects on cell migration were limited across all tested drugs, indicating migration impairment is not a dominant outcome.\"},{\"question\":\"How did the drugs influence intracellular ROS levels, and what was the toxicity profile?\",\"answer\":\"ROS production depended on the cell line and drug: efavirenz increased ROS in PC-3, while saquinavir and ritonavir increased ROS in UM-UC-5 cells. Overall toxicity was minimal in non-malignant cells, with some toxicity for saquinavir only at concentrations higher than those needed for anticancer activity.\"}]","Repurposing Antiretroviral Drugs for Urological Cancers - Differential Effects of Protease Inhibitors and NNRTIs | PDF",1790089238,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da07fe0e1b2127087470143e04d2084b.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff0de24402fcb7d2d5ef6c96ebedd29d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/732e5771e992171083d7e1be082e1f9c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b998f51075373775b4b66bc779350ee.webp",980,1385]